12 results about "Low pathogenic" patented technology

The present invention relates to the field of animal health. Particularly, the present invention relates to an attenuated Duck Enteritis Virus (DEV). More particularly, the present invention relates to an attenuated DEV that shows no or a reduced pathogenicity in duck and chicken. Furthermore, the present invention relates to a composition, comprising the attenuated DEV of the invention as vector-vaccine for poultry, and the use thereof.

The invention discloses application of IL-8 protein in porcine reproductive and respiratory syndrome virus infection, and belongs to the technical field of veterinary biological products. Researches show that IL-8 which indirectly influences the PRRSV infection course by regulating inflammatory response in the prior art also has the effect of directly inhibiting PRRSV. The IL-8 protein can significantly reduce highly pathogenic HP-PRRSV, low pathogenic LP-PRRSV, NADC30-like and recombinant PRRSV infections, and can be developed into drugs for preventing and treating different types of PRRSV infections, so that a brand new thought is provided for PRRS prevention and treatment, the problem that the efficacy of therapeutic drugs is reduced or invalid due to high PRRSV variability is effectively solved, and the application prospect is broad. And the method is of great significance to actual production.

The invention provides a method for detecting H3, H9 and H10 subtype avian influenza viruses through multiple real-time RT-PCR (Reverse Transcription-Polymerase Chain Reaction), and belongs to the technical field of molecular medicines. The primer group, the probe group, the kit and the like are provided, so that one-stop synchronous detection and accurate typing of avian influenza virus subtypes H3, H9 and H10 can be realized, and the detection efficiency is remarkably improved. The method has excellent specificity, can effectively avoid misjudgment, has extremely high detection sensitivity, can find virus traces in the early stage of infection, and strives for precious time for epidemic situation early warning. The method is convenient to operate, stable and reliable in result and easy to popularize and use, provides powerful technical support for daily monitoring and epidemiological investigation of the low-pathogenicity avian influenza in livestock and poultry farms, and has important practical application value for guaranteeing safe production of the breeding industry and preventing public health risks.

A method for screening and efficiently cultivating bezoar strains belongs to the field of bezoar strain screening, and comprises the following steps: step 1, inoculating a culture medium with low-pathogenicity Escherichia coli for culturing, comparing and observing, picking out single colonies with good growth vigor for subculture, and preserving the strains after culture; 2, taking the primarily screened preserved strain, reviving in four regions of an LB solid culture medium by marking lines, selecting a single colony, putting the single colony into a first gradient liquid bile culture medium, culturing, measuring OD600, and if OD600gt is detected, determining that the single colony is not detected; and 0.6, the strain can be placed in a liquid bile culture medium of the next gradient, and the strain which can grow in the three gradients can be inoculated into fresh oxgall for culture. The method has the advantages that the escherichia coli strain with high beta-glucuronidase activity for efficiently cultivating calculus bovis can be obtained, in-vitro cultivation verifies that the escherichia coli strain has bile resistance, calculus bovis analogues can be obtained, and the physicochemical properties of the calculus bovis analogues are similar to those of natural calculus bovis.

The invention relates to the field of animal virology, and relates to separation and identification of a chicken-derived H3N3 avian influenza virus strain and application of the chicken-derived H3N3 avian influenza virus strain in vaccine development. The H3N3 subtype avian influenza virus AIV-S03 strain is preserved in the China General Microbiological Culture Collection Center on May 16, 2024, and the preservation number of the H3N3 subtype avian influenza virus AIV-S03 strain is CGMCC (China General Microbiological Culture Collection Center) No.45981. The AIV-S03 strain provided by the invention is subjected to chick embryo amplification and formaldehyde inactivation, and is respectively mixed with a novel 605 adjuvant and a white oil adjuvant to prepare inactivated vaccines of different dosage forms, immune evaluation is performed through a serological method and an immune challenge method, and the two different adjuvant vaccines can both generate a hemagglutination inhibition antibody with the ratio of 1: 64 or above. The challenge protection rate is 100%, and the feed additive has a good protection effect on poultry groups. The invention has an important value for preventing and treating the low-pathogenicity avian influenza virus.

Bacteria with tumor-targeting capability express, surface displayed, secreted and / or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.

Method for reducing the pathogenicity of pathogens, in particular parasitic molecules, contained in ambient air, in which ambient air containing pathogens is drawn in from the environment on the suction side by means of a compressor (1) and compressed to a pressure of at least 250 kPa and then the air, reduced in its pathogenicity and again reduced to ambient pressure, is released into the environment, wherein the ambient air containing pathogens is passed through a heat exchanger (2) by means of the compressor (1) and heated with a heat pump and the compressed air is kept at a pressure of at least 250 kPa and at a temperature of at least 80 °C and at most 150 °C for a residence time of at least 50 s and is then released back into the environment by flowing through the heat exchanger (2).

The invention provides a preparation method and application of low-pathogenicity avian influenza virus positive serum, and belongs to the technical field of veterinary biological products. The low-pathogenicity avian influenza virus positive serum with high HI titer and neutralizing titer can be obtained by adopting a method of respectively immunizing the live virus and the inactivated vaccine once. The preparation method disclosed by the invention is not limited to the low-pathogenicity avian influenza virus of a single subtype. The positive serum prepared by the method has the characteristics of good specificity, strong sensitivity and the like, and can be used for technical detection of indirect immunofluorescence, western blot, immunohistochemistry and the like; and the kit can also be used for exogenous virus detection of poultry virus live vaccines, separation and identification of clinical viruses, identification and inspection of live vector vaccines, clinical monitoring of avian influenza viruses, epidemiological investigation and immune effect evaluation of related vaccines.

Angiotensin-converting enzyme 2(ACE2) has been confirmed as a specific receptor for several β group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.

The utility model relates to the technical field of virus sample preparation, in particular to a filter for preparing a low-pathogenicity influenza virus detection sample, which is convenient for cleaning solid substances, avoiding blockage, improving the filtering efficiency and ensuring the overall stability of equipment. Comprising a box body, a damping base, a diatom composite layer screen drum, a bamboo charcoal composite layer screen drum, a concentration device, a centrifugal assembly, a collection assembly and a sealing assembly, the bottom end of the box body is connected with the top end of the damping base, the diatom composite layer screen drum and the bamboo charcoal composite layer screen drum are located in the box body, and the concentration device is installed at the bottom end in the box body; a feeding opening is formed in the top end of the box body, the centrifugal assembly is mounted in the box body, the sealing assembly covers the feeding opening of the box body, the collecting assembly is mounted on the inner wall of the lower part of the box body, and the output end of the collecting assembly is connected with the input end of the concentration equipment.

The invention discloses an AQP4-IgG molecular typing detection method and kit for predicting glucocorticoid treatment prognosis of an NMOSD patient, and belongs to the technical field of autoimmune disease diagnosis. The detection method comprises the following steps: preparing patient serum AQP4-IgG, co-incubating the patient serum AQP4-IgG and primary astroglia cells, detecting C3 gene and protein expression quantity through RT-PCR and Western Blot double levels, and comparing with an rAb-53 monoclonal antibody, and judging that the type is a high pathogenic type when the expression quantity is greater than or equal to 1.5 times. The kit comprises an Asian race high-pathogenicity AQP4-IgG standard substance, an rAb-53 reference substance, a C3 detection reagent and an auxiliary reagent. The typing system with 'C3 inductivity' as the core is established for the first time, 20 clinical samples and 12-month follow-up visit verification show that the prognosis reject ratio of patients with high pathogenicity typing is 75%, the prognosis reject ratio of patients with low pathogenicity typing is only 8.3%, early accurate prediction of treatment prognosis is achieved, the blank that existing detection is only qualitative and has no prognosis guidance value is filled, a tool is provided for accurate diagnosis and treatment of NMOSD, and the application prospect is wide.

Bacteria with tumor-targeting capability express, surface displayed, secreted and / or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.